CG Oncology, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCG Oncology is a late-stage clinical biopharmaceutical company solely focused on developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer.
What they do
CG Oncology is developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy with a dual mechanism of action designed to kill cancer cells directly and activate an anti-tumor immune response. The company is currently in Phase 3 clinical development for high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), with a focus on BCG-unresponsive patients. It has no approved products and generates minimal revenue, primarily from collaborations or grants.
Revenue drivers
- Collaboration and grant revenue — Revenue is minimal (less than $5.0M annually) and not from product sales; it comes from collaboration agreements and grant funding, as the company has no commercialized products.
Recent performance
For the quarter ended June 30, 2026, the company reported revenue of $1.2M, compared to $1.1M in the prior quarter (March 31, 2026) and $2.3M in the December 31, 2025 quarter. Annual net loss widened from $88.0M in 2024 to $161.0M in 2025, with operating cash flow of -$132.3M in 2025. As of June 30, 2026, the company held $19.6M in cash and equivalents, but total assets were $1.09B, suggesting significant investments. Diluted EPS improved from -$15.65 in 2023 to -$2.08 in 2025.
Strategy
The company is prioritizing the clinical development of cretostimogene, with a focus on completing the Phase 3 BOND-003 Cohort C trial in high-risk BCG-unresponsive NMIBC with CIS. It plans to submit a Biologics License Application (BLA) to the FDA in the fourth quarter of 2026. Management is also exploring an expanded development program through BOND-003 Cohort P, an exploratory study. To fund operations, the company has utilized an Open Market Sale Agreement with Jefferies LLC, raising approximately $550.0M and increasing the available shares by an additional $500.0M in August 2026.
Risks
- Single product candidate — The business depends entirely on cretostimogene; any clinical or regulatory failure would materially harm the company.
- Clinical trial execution — Delays or unfavorable results in the ongoing Phase 3 BOND-003 trial could prevent or delay BLA submission and approval.
- Regulatory approval uncertainty — The FDA has not yet approved cretostimogene; receipt of Breakthrough Therapy designation does not guarantee approval.
- Cash burn and dilution — The company has no product revenue and is burning cash at an increasing rate, relying on equity sales that dilute shareholders.
Outlook
Management expects to complete the BLA submission for cretostimogene in the fourth quarter of 2026, based on data from BOND-003 Cohort C. They highlight potentially best-in-disease complete response rates of 75.5% and durable responses through 24 months, as published in The Lancet Oncology. The company is also assessing an earlier-stage cohort (Cohort P) and may pursue additional indications beyond high-risk NMIBC, but no timelines are disclosed beyond the BLA.